%0 Journal Article %A Surakameth Mahasirimongkol %A Athiwat Khunphon %A Oraya Kwangsukstid %A Sompong Sapsutthipas %A Minkwan Wichaidit %A Archawin Rojanawiwat %A Nuanjun Wichuckchinda %A Wiroj Puangtubtim %A Warangluk Pimpapai %A Sakulrat Soonthorncharttrawat %A Asawin Wanitchang %A Anan Jongkaewwattana %A Kanjana Srisutthisamphan %A Daraka Phainupong %A Penpitcha Thawong %A Pundharika Piboonsiri %A Warittha Sawaengdee %A Thitiporn Somporn %A Kanokphon Ritthitham %A Supaporn Chumpol %A Nadthanan Pinyosukhee %A Rattanawadee Wichajarn %A Panadda Dhepaksorn %A Sopon Iamsiritahworn %A Supaporn Phumiamorn %T Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine %D 2021 %R 10.1101/2021.11.05.21264700 %J medRxiv %P 2021.11.05.21264700 %X Background Responding to SARS-CoV-2 Delta variants escaped the vaccine-induced immunity and waning immunity from the inactivated whole virus vaccine, Thailand recently proposed a heterologous inactivated whole virus vaccine (CoronaVac) viral vector vaccine (ChAdOx1 nCoV-19) prime-boost vaccine regimen(I/V). This study aims to evaluate the immunogenicity and adverse events of this regimen by comparison with homologous CoronaVac, ChAdOx1 nCoV-19, and convalescent serum.Method Immunogenicity was evaluated by the level of IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (S1 subunit) (anti-S RBD). At 2 weeks following the second dosage, a selection of random samples was tested for plaque reduction neutralisation (PRNT) and Pseudotype-Based Microneutralization test (PVNT) against SARS-CoV-2 variants of concern (VOCs). The safety profile of heterologous CoronaVac-ChAdOx1 nCoV-19 prime-boost vaccine regimen was described by interviewing at the 1-month visit.Result Between April to August 2021,426 participants were included in the study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19(I/V),32 obtaining homologous CoronaVac(I/I),47 obtaining homologous ChAdOx1 nCoV-19(V/V),169 with history covid-19 infection. Geometric mean titers (GMTs) of anti-S RBD level in the I/V group compare 2wks and 4 wks (873.9 vs 639,p=0.00114).At 4 wks, GMTs of anti-S RBD level in I/V group was 639, 95% CI 63-726,and natural infection group 177.3, 95% CI 42-221, and V/V group 211.1, 95% CI 77-152, and I/I group 108.2, 95% CI 77-152; all p<0.001).At 2 wks, The GMTs of 50%PRNT of 19 sampling from the I/V group is 434.5, 95% CI 326-579, against wild type and 80.4, 95% CI 56-115, against alpha and 67.4, 95% CI 48-95, against delta and 19.8, 95% CI 14-30, against beta; all p<0.001. At 2 wks, The GMTs of 50%PVNT of 15 sampling from the I/V group is 597.8, 95% CI 368-970, against wild type and 163.9, 95% CI 89-301, against alpha and 157.7, 95% CI 66-378, against delta. The AEs in the I/V schedule were well tolerated and generally unremarkable.Conclusion The I/V vaccination is a mixed regimen that induced higher immunogenicity and shall be considered for responding to Delta Variants when only inactivated whole virus vaccine and viral vector vaccine was available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDepartment of Medical Sciences provided funding for this project. Studies, data collection, analysis, and interpretation, as well as manuscript preparation and the determination to submit the paper for publication, were all independent of funding sources.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee,Department of Medical Sciences,Ministry of Public Health,Thailand has approved the following study which is to be carried out in compliance with ICH-GCP and 45 CFR 46.101(b)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript . Surakameth Mahasirimongkol, MD, Ph.D. Medical Life Sciences Institute, Department of Medical Sciences, Ministry of Public Health 88/7 Tivanond Road, Nonthaburi 11000, Thailand Tel: (+66) 2951000, 0-2589-9580-8; Fax: (+66) 2-591-1707 E-mail: Surakameth.m{at}dmsc.mail.go.th. or surakameth{at}hotmail.com %U https://www.medrxiv.org/content/medrxiv/early/2021/11/12/2021.11.05.21264700.full.pdf